CNDAP partners with Takeda to develop new therapies for Alzheimer’s disease and associated brain disorders


Millions of people in the United States and around the world who suffer or are at risk of developing Alzheimer’s disease are desperate for new solutions to prevent or stop the devastating effects of this disease. Currently available treatments are inadequate and more effective strategies are urgently needed.

The new collaboration between CNDAP and Takeda will help address this critical need. It builds on discoveries made by a team of scientists led by Lennart Mucke, MD, director of the Gladstone Institute of Neurological Diseases. Their research has led to a better understanding of the biology of tau. They have also developed informative experimental models and innovative tests to identify and evaluate drugs that can reduce overall levels of tau in neurons.

Researchers in academia and industry are increasingly interested in this therapeutic strategy, as evidence accumulates that tau promotes the development of Alzheimer’s disease and other brain disorders, and because many Strategies targeting amyloid proteins have failed in clinical trials.

Mucke works in close collaboration with Anke Meyer-Franke, PhD, director of the Assay Development and Drug Discovery Core at Gladstone. Together, they have developed a unique test that can screen thousands of chemical compounds and assess their impact on tau protein levels in individual neurons.

Using this test, Mucke and his team identified small molecules that lower tau levels in neurons without causing neurotoxicity. The CNDAP-Takeda collaboration will focus on the development of these promising molecules in new drugs for Alzheimer’s disease and on the identification of additional molecules with high therapeutic potential.

“We have shown that lowering overall tau levels reduces brain dysfunction in experimental models of Alzheimer’s disease, epilepsy and autism,” explains Mucke. “Collaboration with CNDAP and Takeda should help us take this exciting translational project to the finish line: the development of better treatments to prevent and slow the progression of Alzheimer’s disease and related conditions.

The people and funding organizations who supported the research in Mucke’s lab that led to the establishment of this drug development program include the Alzheimer’s Association, the National Institutes of Health, the Carroll Obremskey Charitable Fund, the Charles and Helen Schwab Foundation, Dan Ullyot, and the Tau Consortium.

To further develop and market this program and other Gladstone translation programs, Cure Network Ventures (a for-profit affiliate owned by Gladstone) founded CNDAP with family office Dolby, which provided most of the financial support. Since its inception, CNDAP has also attracted investment from the Rainwater Charitable Foundation.

“Lowering overall tau levels is a very promising therapeutic approach,” said David Dolby, CEO of Dolby Family Ventures and member of the board of directors of CNDAP. “We want to make sure that the cutting-edge research from Gladstone Laboratories can lead to real treatments that can help the millions of people with conditions like Alzheimer’s disease, and the partnership with Takeda is essential to achieve that goal.”

This research collaboration will leverage Takeda’s arsenal of diverse drug development approaches for neurodegenerative disorders to optimize lead compounds, advance development candidates into clinical trials, and bring the drugs to market. most promising as a new treatment for Alzheimer’s disease.

“The ability to reduce tau levels in the brain may offer a new avenue for treating some of the most devastating neurodegenerative diseases, and we welcome the opportunity to partner with Professor Mucke and CNDAP to advance this area of ​​research. exciting research towards the clinic, “said Ceri Davies, PhD, Head of Neuroscience Drug Discovery at Takeda. “We value collaborations wherever they originate, and this program emphasizes the importance of academic-industry partnerships where we can combine the discoveries made by renowned scientists at the Gladstone Institutes with our translation capabilities and the speed to accelerate. the development of new therapies with transformative potential for patients. “

“Thanks to our important partners CNDAP and Takeda, we are able to go beyond what is typically possible for academic and nonprofit institutions,” says Stephen freedman, PhD, Vice President for Corporate and Enterprise Liaison at Gladstone. “We continually strive to explore bold translational models, combine our strengths with the expertise of external partners and offer a range of new investment opportunities with the overall goal of accelerating the translation of our scientific findings into new therapies. “

About Cure Network’s Dolby Acceleration Partners
Cure Network Dolby Acceleration Partners LLC (CNDAP) was founded in 2015 as a partnership between Cure Network Ventures, a company 100% owned by Gladstone Institutes, and the Dolby family office. CNDAP promotes the translational advancement of Gladstone’s fundamental discoveries by bridging the gap between academia and industry. Its main goal is the discovery of small molecules and other therapies that could transform the treatment of Alzheimer’s disease and associated neurological disorders. The CNDAP operating model combines promising scientific programs ready to be translated with suitable sources of funding and serves as a catalyst for the creation of spin-off companies and partnerships with biotechnology and pharmaceutical companies. The CNDAP was founded around two innovative research programs using distinct approaches for the treatment of Alzheimer’s disease, from the laboratories of Lennart Mucke, MD and Jorge palop, PhD, at the Gladstone Institutes.

About Gladstone Institutes
To ensure that our work does the greatest good, Gladstone Institutes focus on conditions with profound medical, economic and social impact – unresolved diseases. Gladstone is an independent, non-profit life science research organization that uses visionary science and technology to beat disease. He has an academic affiliation with the University of California, San Francisco.

Media contact:
Julie langelier
Associate Director
Communication
[email protected]
415.734.5000

Gladstone Institutes

Related links

https://gladstone.org


About Margie Peters

Check Also

My day: Grainne Hughes, Almac Pharma Services

At 8am, I’m in my car and already halfway from the office to Almac’s headquarters …

Leave a Reply

Your email address will not be published.